This site is intended for healthcare professionals

Over the horizon: early stage trials for NASH

Read time: 10 mins
Last updated:2nd Sep 2020
Published:2nd Sep 2020
Find out about drug therapies in the very early stages of development for the treatment of NASH, the benefits of combination drug treatments and new detection methods that could overcome the challenges of detecting NASH.

Another dozen or so drugs are in early stage trials. Most notably, VBL Therapeutics is currently testing lecinoxoids VB 201 and VB 703, antagonists for Toll-like receptors 2 and 4 (TLR-2 and TLR-4), which play a role in nonalcoholic fatty liver disease. 

In an exploratory trial, VB 201 demonstrated significant reduction of vascular inflammation, suggesting that lecinoxoids can restrict liver inflammation and ameliorate liver fibrosis.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.